Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 20/20 | 0.87 |
| ▸ | GABRP | O00591 | 2/20 | 0.79 |
| ▸ | GABRD | O14764 | 2/20 | 0.79 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.79 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.79 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.79 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.79 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.79 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.79 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.79 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.79 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.79 |
| ▸ | GABRE | P78334 | 2/20 | 0.79 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.79 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.79 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.79 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.79 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.79 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.79 |
| ▸ | PGR | P06401 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29378261 | 1.00 | AR (0.87) | ARGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL547539 | 0.98 | AR (0.87) | ARGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL29861461 | 0.98 | AR (0.87) | ARGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL15661295 | 0.98 | AR (0.85) | ARGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL17107302 | 0.98 | AR (0.85) | ARGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL17107300 | 0.95 | AR (0.78) | ARGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL17117389 | 0.95 | AR (0.78) | ARGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL17117368 | 0.95 | AR (0.78) | ARGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL17107295 | 0.94 | AR (0.85) | ARGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL14930979 | 0.93 | AR (1.00) | ARGABRPGABRDGABRA1GABRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 166 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE50642-E1 | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer | ARAGON PHARMACEUTICALS, INC. (US) | 2025-10-21 | — | — | US | claimed |
| US-RE49353-E1 | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer | ARAGON PHARMACEUTICALS, INC. (US) | 2023-01-03 | — | — | US | claimed |
| US-20220160695-A1 | ANTI-ANDROGENS FOR THE TREATMENT OF METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER | ARAGON PHARMACEUTICALS, INC. | 2022-05-26 | — | — | US | claimed |
| EP-3917519-A1 | ANTI-ANDROGENS FOR THE TREATMENT OF METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER | Aragon Pharmaceuticals, Inc. (US) | 2021-12-08 | — | — | EP | claimed |
| WO-2020157699-A1 | ANTI-ANDROGENS FOR THE TREATMENT OF METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER | ARAGON PHARMACEUTICALS, INC. (US) | 2020-08-06 | — | — | WO | claimed |
| EP-3610876-A1 | ANTI-ANDROGENS IN COMBINATION WITH ABIRATERONE ACETATE AND PREDNISONE FOR TREATING PROSTATE CANCER | Aragon Pharmaceuticals, Inc. (US) | 2020-02-19 | — | — | EP | claimed |
| US-20180318277-A1 | Anti-Androgens For The Treatment Of Non-Metastatic Castrate-Resistant Prostate Cancer | ARAGON PHARMACEUTICALS INC (US) | 2018-11-08 | — | — | US | claimed |
| US-10052314-B2 | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer | ARAGON PHARMACEUTICALS, INC. (US) | 2018-08-21 | — | — | US | claimed |
| US-20180110764-A1 | Anti-Androgens For The Treatment Of Non-Metastatic Castrate-Resistant Prostate Cancer | ARAGON PHARMACEUTICALS INC (US) | 2018-04-26 | — | — | US | claimed |
| EP-3305285-A1 | ANTI-ANDROGENS FOR THE TREATMENT OF NON-METASTATIC CASTRATE-RESISTANT PROSTATE CANCER | Aragon Pharmaceuticals, Inc. (US) | 2018-04-11 | — | — | EP | claimed |
| US-9884054-B2 | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer | ARAGON PHARMACEUTICALS, INC. (US) | 2018-02-06 | — | — | US | claimed |
| EP-2900224-A1 | ANTI-ANDROGENS FOR THE TREATMENT OF NON-METASTATIC CASTRATE-RESISTANT PROSTATE CANCER | Aragon Pharmaceuticals, Inc. (US) | 2015-08-05 | — | — | EP | claimed |
| US-20140088129-A1 | ANTI-ANDROGENS FOR THE TREATMENT OF NON-METASTATIC CASTRATE-RESISTANT PROSTATE CANCER | ARAGON PHARMACEUTICALS, INC. (US) | 2014-03-27 | — | — | US | claimed |
| US-20130034501-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-02-07 | — | — | US | claimed |
| EP-1893196-A4 | DIARYLHYDANTOIN COMPOUNDS | UNIV CALIFORNIA (US) | 2009-03-18 | — | — | EP | claimed |
| JP-2008540523-A | — | — | 2008-11-20 | — | — | JP | claimed |
| EP-1893196-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-03-05 | — | — | EP | claimed |
| US-20070004753-A1 | N-methyl-4-{4-[7-(4-cyano-3 -trifluoromethylphenyl)-6,8-dioxo-5,7-diazaspiro[3.4]oct-5-yl]-phenyl}butyramide; for treatment of hormone refractory prostate cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-01-04 | — | — | US | claimed |
| WO-2006124118-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-11-23 | — | — | WO | claimed |
| US-20250333385-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-10-30 | — | — | US | disclosed |
| US-RE50642-E1 | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer | ARAGON PHARMACEUTICALS, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| US-12303497-B2 | Anti-androgens for the treatment of metastatic castration-sensitive prostate cancer | ARAGON PHARMACEUTICALS, INC. (US) | 2025-05-20 | — | — | US | disclosed |
| US-20240165091-A1 | ANTI-ANDROGENS FOR THE TREATMENT OF METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER | ARAGON PHARMACEUTICALS INC (US) | 2024-05-23 | — | — | US | disclosed |
| US-20240132452-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-04-25 | — | — | US | disclosed |
| US-11963952-B2 | Anti-androgens for the treatment of metastatic castration-sensitive prostate cancer | ARAGON PHARMACEUTICALS, INC. (US) | 2024-04-23 | — | — | US | disclosed |
| US-11903937-B2 | — | — | 2024-02-20 | — | — | US | disclosed |
| US-20230405094-A1 | TREATMENT OR PREVENTION OF A DISEASE OR DISORDER | Janssen Sciences Ireland Unlimited Company (IE) | 2023-12-21 | — | — | US | disclosed |
| US-20230338351-A1 | Androgen Receptor Inhibitors For The Treatment Of Non-Metastatic Castration-Resistant Prostate Cancer In Subjects With Severe Hepatic Impairment | ARAGON PHARMACEUTICALS INC (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230338351-A1 | Androgen Receptor Inhibitors For The Treatment Of Non-Metastatic Castration-Resistant Prostate Cancer In Subjects With Severe Hepatic Impairment | ARAGON PHARMACEUTICALS INC (US) | 2023-10-26 | — | — | US | disclosed |
| EP-3357513-B1 | PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | KANGPU BIOPHARMACEUTICALS LTD (CN) | 2023-10-25 | — | — | EP | disclosed |
| EP-4247333-A1 | TREATMENT OR PREVENTION OF A DISEASE OR DISORDER | Janssen Sciences Ireland Unlimited Company (IE) | 2023-09-27 | — | — | EP | disclosed |
| US-11723898-B2 | Androgen receptor inhibitors for the treatment of non-metastatic castration-resistant prostate cancer in subjects with severe hepatic impairment | ARAGON PHARMACEUTICALS, INC. (US) | 2023-08-15 | — | — | US | disclosed |
| US-11723898-B2 | Androgen receptor inhibitors for the treatment of non-metastatic castration-resistant prostate cancer in subjects with severe hepatic impairment | ARAGON PHARMACEUTICALS, INC. (US) | 2023-08-15 | — | — | US | disclosed |
| US-20230190722-A1 | ANTI-ANDROGENS FOR THE TREATMENT OF METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER | ARAGON PHARMACEUTICALS INC (US) | 2023-06-22 | — | — | US | disclosed |
| US-20230190722-A1 | ANTI-ANDROGENS FOR THE TREATMENT OF METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER | ARAGON PHARMACEUTICALS INC (US) | 2023-06-22 | — | — | US | disclosed |
| US-20230109968-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-04-13 | — | — | US | disclosed |
| US-20230014124-A1 | HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2023-01-19 | — | — | US | disclosed |
| US-RE49353-E1 | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer | ARAGON PHARMACEUTICALS, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-RE49353-E1 | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer | ARAGON PHARMACEUTICALS, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| EP-4054572-A1 | ANDROGEN RECEPTOR INHIBITORS FOR THE TREATMENT OF NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER IN SUBJECTS WITH SEVERE HEPATIC IMPAIRMENT | Aragon Pharmaceuticals, Inc. (US) | 2022-09-14 | — | — | EP | disclosed |
| WO-2022106487-A1 | TREATMENT OR PREVENTION OF A DISEASE OR DISORDER | Janssen Sciences Ireland Unlimited Company (IE) | 2022-05-27 | — | — | WO | disclosed |
| US-20220160695-A1 | ANTI-ANDROGENS FOR THE TREATMENT OF METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER | ARAGON PHARMACEUTICALS, INC. | 2022-05-26 | — | — | US | disclosed |
| US-20220160695-A1 | ANTI-ANDROGENS FOR THE TREATMENT OF METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER | ARAGON PHARMACEUTICALS, INC. | 2022-05-26 | — | — | US | disclosed |
| EP-3970721-A1 | DIARYLHYDANTOIN COMPOUNDS AS ANDROGEN RECEPTOR ANTAGONISTS FOR TREATMENT OF CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-03-23 | — | — | EP | disclosed |
| EP-3917519-A1 | ANTI-ANDROGENS FOR THE TREATMENT OF METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER | Aragon Pharmaceuticals, Inc. (US) | 2021-12-08 | — | — | EP | disclosed |
| US-11185592-B2 | Spirocyclic degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-20210238145-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-08-05 | — | — | US | disclosed |
| US-20210238145-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-08-05 | — | — | US | disclosed |
| EP-3527210-B1 | COMBINED COMPOSITION COMPRISING A BENZOHETEROCYCLIC COMPOUND AND AN ANDROGEN RECEPTOR PATHWAY MODULATOR AND USES THEREOF | KANGPU BIOPHARMACEUTICALS LTD (CN) | 2021-06-09 | — | — | EP | disclosed |
| US-20210128541-A1 | ANDROGEN RECEPTOR INHIBITORS FOR THE TREATMENT OF NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER IN SUBJECTS WITH SEVERE HEPATIC IMPAIRMENT | ARAGON PHARMACEUTICALS, INC. | 2021-05-06 | — | — | US | disclosed |
| US-20210128541-A1 | ANDROGEN RECEPTOR INHIBITORS FOR THE TREATMENT OF NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER IN SUBJECTS WITH SEVERE HEPATIC IMPAIRMENT | ARAGON PHARMACEUTICALS, INC. | 2021-05-06 | — | — | US | disclosed |
| US-20210113545-A1 | Pharmaceutical Composition Comprising a Benzoheterocyclic Compound and Androgen Receptor Pathway Modulator and Application Thereof | KANGPU BIOPHARMACEUTICALS LTD (CN) | 2021-04-22 | — | — | US | disclosed |
| US-20210106688-A1 | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2021-04-15 | — | — | US | disclosed |
| US-20210069154-A1 | Treatment of Breast Cancer | MEDIVATION PROSTATE THERAPEUTICS LLC | 2021-03-11 | — | — | US | disclosed |
| US-10933059-B2 | Combination, application thereof and treatment method | KANGPU BIOPHARMACEUTICALS. LTD. (CN) | 2021-03-02 | — | — | US | disclosed |
| EP-3777845-A1 | ANTI-ANDROGENS FOR THE TREATMENT OF NON-METASTATIC CASTRATE-RESISTANT PROSTATE CANCER | Aragon Pharmaceuticals, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| EP-3777845-A1 | ANTI-ANDROGENS FOR THE TREATMENT OF NON-METASTATIC CASTRATE-RESISTANT PROSTATE CANCER | Aragon Pharmaceuticals, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| US-10905768-B1 | Heterocyclic degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2021-02-02 | — | — | US | disclosed |
| US-20210000812-A1 | Anti-Androgens For The Treatment Of Non-Metastatic Castrate-Resistant Prostate Cancer | ARAGON PHARMACEUTICALS INC (US) | 2021-01-07 | — | — | US | disclosed |
| US-20210000812-A1 | Anti-Androgens For The Treatment Of Non-Metastatic Castrate-Resistant Prostate Cancer | ARAGON PHARMACEUTICALS INC (US) | 2021-01-07 | — | — | US | disclosed |
| US-10849888-B2 | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer | ARAGON PHARMACEUTICALS, INC. (US) | 2020-12-01 | — | — | US | disclosed |
| US-10849888-B2 | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer | ARAGON PHARMACEUTICALS, INC. (US) | 2020-12-01 | — | — | US | disclosed |
| US-20200354334-A1 | Process For The Preparation Of A Diarylthiohydantoin Compound | ARAGON PHARMACEUTICALS INC (US) | 2020-11-12 | — | — | US | disclosed |
| US-10799489-B2 | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer | ARAGON PHARMACEUTICALS, INC. (US) | 2020-10-13 | — | — | US | disclosed |
| US-10799489-B2 | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer | ARAGON PHARMACEUTICALS, INC. (US) | 2020-10-13 | — | — | US | disclosed |
| US-10799488-B2 | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer | ARAGON PHARMACEUTICALS, INC. (US) | 2020-10-13 | — | — | US | disclosed |
| US-10799488-B2 | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer | ARAGON PHARMACEUTICALS, INC. (US) | 2020-10-13 | — | — | US | disclosed |
| EP-3305285-B1 | ANTI-ANDROGENS FOR THE TREATMENT OF NON-METASTATIC CASTRATE-RESISTANT PROSTATE CANCER | ARAGON PHARMACEUTICALS INC (US) | 2020-09-02 | — | — | EP | disclosed |
| WO-2020157699-A1 | ANTI-ANDROGENS FOR THE TREATMENT OF METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER | ARAGON PHARMACEUTICALS, INC. (US) | 2020-08-06 | — | — | WO | disclosed |
| US-20200079741-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-03-12 | — | — | US | disclosed |
| US-20190328722-A1 | COMBINATION, APPLICATION THEREOF AND TREATMENT METHOD | KANGPU BIOPHARMACEUTICALS, LTD. (CN) | 2019-10-31 | — | — | US | disclosed |
| US-20190269667-A1 | Anti-Androgens For The Treatment Of Non-Metastatic Castrate-Resistant Prostate Cancer | ARAGON PHARMACEUTICALS INC (US) | 2019-09-05 | — | — | US | disclosed |
| US-20190269667-A1 | Anti-Androgens For The Treatment Of Non-Metastatic Castrate-Resistant Prostate Cancer | ARAGON PHARMACEUTICALS INC (US) | 2019-09-05 | — | — | US | disclosed |
| US-20190269668-A1 | Anti-Androgens For The Treatment Of Non-Metastatic Castrate-Resistant Prostate Cancer | ARAGON PHARMACEUTICALS INC (US) | 2019-09-05 | — | — | US | disclosed |
| US-20190269668-A1 | Anti-Androgens For The Treatment Of Non-Metastatic Castrate-Resistant Prostate Cancer | ARAGON PHARMACEUTICALS INC (US) | 2019-09-05 | — | — | US | disclosed |
| US-20190262315-A1 | Treatment of Breast Cancer | MEDIVATION PROSTATE THERAPEUTICS, INC. | 2019-08-29 | — | — | US | disclosed |
| EP-3527210-A1 | COMPOSITION, APPLICATION THEREOF AND TREATMENT METHOD | Kangpu Biopharmaceuticals, Ltd. (CN) | 2019-08-21 | — | — | EP | disclosed |
| US-20190210974-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-07-11 | — | — | US | disclosed |
| US-20190210974-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-07-11 | — | — | US | disclosed |
| US-20180318277-A1 | Anti-Androgens For The Treatment Of Non-Metastatic Castrate-Resistant Prostate Cancer | ARAGON PHARMACEUTICALS INC (US) | 2018-11-08 | — | — | US | disclosed |
| US-10052314-B2 | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer | ARAGON PHARMACEUTICALS, INC. (US) | 2018-08-21 | — | — | US | disclosed |
| EP-3357513-A1 | PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | Kangpu Biopharmaceuticals, Ltd. (CN) | 2018-08-08 | — | — | EP | disclosed |
| US-20180110764-A1 | Anti-Androgens For The Treatment Of Non-Metastatic Castrate-Resistant Prostate Cancer | ARAGON PHARMACEUTICALS INC (US) | 2018-04-26 | — | — | US | disclosed |
| US-20180110764-A1 | Anti-Androgens For The Treatment Of Non-Metastatic Castrate-Resistant Prostate Cancer | ARAGON PHARMACEUTICALS INC (US) | 2018-04-26 | — | — | US | disclosed |
| EP-3305285-A1 | ANTI-ANDROGENS FOR THE TREATMENT OF NON-METASTATIC CASTRATE-RESISTANT PROSTATE CANCER | Aragon Pharmaceuticals, Inc. (US) | 2018-04-11 | — | — | EP | disclosed |
| US-20180086718-A1 | Diarylhydantoin Compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-03-29 | — | — | US | disclosed |
| US-20180086718-A1 | Diarylhydantoin Compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-03-29 | — | — | US | disclosed |
| US-20180055915-A1 | COMPOSITIONS AND METHODS FOR TREATING PROSTATE CANCER | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2018-03-01 | — | — | US | disclosed |
| US-20180055915-A1 | COMPOSITIONS AND METHODS FOR TREATING PROSTATE CANCER | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2018-03-01 | — | — | US | disclosed |
| US-9884054-B2 | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer | ARAGON PHARMACEUTICALS, INC. (US) | 2018-02-06 | — | — | US | disclosed |
| US-9884054-B2 | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer | ARAGON PHARMACEUTICALS, INC. (US) | 2018-02-06 | — | — | US | disclosed |
| US-20170101384-A1 | ANDROGEN RECEPTOR ANTAGONISTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2017-04-13 | — | — | US | disclosed |
| US-20170087132-A1 | Treatment of Breast Cancer | MEDIVATION PROSTATE THERAPEUTICS LLC | 2017-03-30 | — | — | US | disclosed |
| EP-3106162-A1 | DIARYLHYDANTOIN COMPOUNDS AS ANDROGEN RECEPTOR ANTAGONISTS FOR TREATMENT OF CANCER | The Regents of the University of California (US) | 2016-12-21 | — | — | EP | disclosed |
| EP-3106162-A1 | DIARYLHYDANTOIN COMPOUNDS AS ANDROGEN RECEPTOR ANTAGONISTS FOR TREATMENT OF CANCER | The Regents of the University of California (US) | 2016-12-21 | — | — | EP | disclosed |
| US-9517229-B2 | Treatment of breast cancer | MEDIVATION PROSTATE THERAPEUTICS, INC. (US) | 2016-12-13 | — | — | US | disclosed |
| EP-2792674-B1 | IMIDAZOLIDINEDIONE COMPOUNDS AND THEIR USES | HINOVA PHARMACEUTICAL INC (CN) | 2016-05-25 | — | — | EP | disclosed |
| US-9346764-B2 | Imidazolidinedione compounds and their uses | HINOVA PHARMACEUTICALS INC. (CN) | 2016-05-24 | — | — | US | disclosed |
| EP-3020706-A1 | DIARYLTHIOHYDANTOIN COMPOUNDS USEFUL FOR THE TREATMENT OF A HYPERPROLIFERATIVE DISORDER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-05-18 | — | — | EP | disclosed |
| EP-3020706-A1 | DIARYLTHIOHYDANTOIN COMPOUNDS USEFUL FOR THE TREATMENT OF A HYPERPROLIFERATIVE DISORDER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-05-18 | — | — | EP | disclosed |
| WO-2015196144-A2 | ANDROGEN RECEPTOR ANTAGONISTS | ENGLAND PAMELA M (US) | 2015-12-23 | — | — | WO | disclosed |
| US-9205102-B2 | Method for treatment of castration-resistant prostate cancer | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2015-12-08 | — | — | US | disclosed |
| US-9126941-B2 | Treatment of hyperproliferative disorders with diarylhydantoin compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-09-08 | — | — | US | disclosed |
| US-9126941-B2 | Treatment of hyperproliferative disorders with diarylhydantoin compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-09-08 | — | — | US | disclosed |
| EP-2900224-A1 | ANTI-ANDROGENS FOR THE TREATMENT OF NON-METASTATIC CASTRATE-RESISTANT PROSTATE CANCER | Aragon Pharmaceuticals, Inc. (US) | 2015-08-05 | — | — | EP | disclosed |
| EP-1893196-B2 | DIARYLHYDANTOIN COMPOUND | UNIV CALIFORNIA (US) | 2015-07-29 | — | — | EP | disclosed |
| EP-1893196-B2 | DIARYLHYDANTOIN COMPOUND | UNIV CALIFORNIA (US) | 2015-07-29 | — | — | EP | disclosed |
| US-20150157656-A1 | Method for Treatment of Castration-Resistant Prostate Cancer | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2015-06-11 | — | — | US | disclosed |
| US-20150112082-A1 | DIARYLHYDANTOIN COMPOUNDS | HOWARD HUGHES MEDICAL INSTITUTE | 2015-04-23 | — | — | US | disclosed |
| US-20150112082-A1 | DIARYLHYDANTOIN COMPOUNDS | HOWARD HUGHES MEDICAL INSTITUTE | 2015-04-23 | — | — | US | disclosed |
| EP-2444085-B1 | Diarylhydantoin compounds as androgen receptor antagonists for treatment of cancer | UNIV CALIFORNIA (US) | 2015-03-18 | — | — | EP | disclosed |
| EP-2444085-B1 | Diarylhydantoin compounds as androgen receptor antagonists for treatment of cancer | UNIV CALIFORNIA (US) | 2015-03-18 | — | — | EP | disclosed |
| US-20140371284-A1 | IMIDAZOLIDINEDIONE COMPOUNDS AND THEIR USES | HC PHARMACEUTICAL CO., LTD. (CN) | 2014-12-18 | — | — | US | disclosed |
| US-20140343111-A1 | DIARYLTHIOHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-11-20 | — | — | US | disclosed |
| US-20140343111-A1 | DIARYLTHIOHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-11-20 | — | — | US | disclosed |
| EP-2013187-B1 | DIARYLTHIOHYDANTOIN COMPOUNDS | UNIV CALIFORNIA (US) | 2014-10-29 | — | — | EP | disclosed |
| EP-2792674-A1 | IMIDAZOLIDINEDIONE COMPOUNDS AND THEIR USES | HC Pharmaceutical Co., Ltd. (CN) | 2014-10-22 | — | — | EP | disclosed |
| US-20140296312-A1 | TREATMENT OF BREAST CANCER | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2014-10-02 | — | — | US | disclosed |
| US-20140088129-A1 | ANTI-ANDROGENS FOR THE TREATMENT OF NON-METASTATIC CASTRATE-RESISTANT PROSTATE CANCER | ARAGON PHARMACEUTICALS, INC. (US) | 2014-03-27 | — | — | US | disclosed |
| US-20140088129-A1 | ANTI-ANDROGENS FOR THE TREATMENT OF NON-METASTATIC CASTRATE-RESISTANT PROSTATE CANCER | ARAGON PHARMACEUTICALS, INC. (US) | 2014-03-27 | — | — | US | disclosed |
| US-8658681-B2 | — | — | 2014-02-25 | — | — | US | disclosed |
| US-8658681-B2 | — | — | 2014-02-25 | — | — | US | disclosed |
| US-8648105-B2 | Diarylthiohydantoin compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-02-11 | — | — | US | disclosed |
| US-8648105-B2 | Diarylthiohydantoin compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-02-11 | — | — | US | disclosed |
| US-20140031409-A1 | METHODS FOR TREATING ANDROGEN RECEPTOR DEPENDENT DISORDERS INCLUDING CANCERS | SANTARIS PHARMA A/S (DK) | 2014-01-30 | — | — | US | disclosed |
| WO-2013066440-A9 | TREATMENT OF BREAST CANCER | MEDIVATION PROSTATE THERAPEUTICS, INC. (US) | 2013-07-18 | — | — | WO | disclosed |
| US-8450290-B2 | Methods for treating androgen receptor dependent disorders including cancers | ENZON PHARMACEUTICALS, INC. (US) | 2013-05-28 | — | — | US | disclosed |
| WO-2013066440-A1 | TREATMENT OF BREAST CANCER | MEDIVATION PROSTATE THERAPEUTICS, INC. (US) | 2013-05-10 | — | — | WO | disclosed |
| EP-2561871-A1 | Diarylhydantoin compounds as androgen receptor antagonists for treatment of cancer | The Regents of The University of California (US) | 2013-02-27 | — | — | EP | disclosed |
| EP-2561871-A1 | Diarylhydantoin compounds as androgen receptor antagonists for treatment of cancer | The Regents of The University of California (US) | 2013-02-27 | — | — | EP | disclosed |
| US-20130034501-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-02-07 | — | — | US | disclosed |
| US-20130034501-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-02-07 | — | — | US | disclosed |
| US-20120295944-A1 | TREATMENT OF HYPERPROLIFERATIVE DISORDERS WITH DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-11-22 | — | — | US | disclosed |
| US-20120295944-A1 | TREATMENT OF HYPERPROLIFERATIVE DISORDERS WITH DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-11-22 | — | — | US | disclosed |
| US-20120190718-A1 | DIARYLTHIOHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-07-26 | — | — | US | disclosed |
| US-20120190718-A1 | DIARYLTHIOHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-07-26 | — | — | US | disclosed |
| US-8183274-B2 | Treatment of hyperproliferative disorders with diarylhydantoin compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-05-22 | — | — | US | disclosed |
| US-8183274-B2 | Treatment of hyperproliferative disorders with diarylhydantoin compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-05-22 | — | — | US | disclosed |
| WO-2012065051-A1 | COMPOSITIONS AND METHODS FOR TREATING ANDROGEN RECEPTOR DEPENDENT DISORDERS INCLUDING CANCERS | ENZON PHARMACEUTICALS, INC. (US) | 2012-05-18 | — | — | WO | disclosed |
| EP-2444085-A1 | Diarylhydantoin compounds as androgen receptor antagonists for treatment of cancer | The Regents of The University of California (US) | 2012-04-25 | — | — | EP | disclosed |
| EP-2444085-A1 | Diarylhydantoin compounds as androgen receptor antagonists for treatment of cancer | The Regents of The University of California (US) | 2012-04-25 | — | — | EP | disclosed |
| US-8110594-B2 | Diarylthiohydantoin compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-02-07 | — | — | US | disclosed |
| US-8110594-B2 | Diarylthiohydantoin compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-02-07 | — | — | US | disclosed |
| EP-1893196-B1 | DIARYLHYDANTOIN COMPOUND | UNIV CALIFORNIA (US) | 2012-01-18 | — | — | EP | disclosed |
| EP-1893196-B1 | DIARYLHYDANTOIN COMPOUND | UNIV CALIFORNIA (US) | 2012-01-18 | — | — | EP | disclosed |
| US-20110152348-A1 | METHODS FOR TREATING ANDROGEN RECEPTOR DEPENDENT DISORDERS INCLUDING CANCERS | ENZON PHARMACEUTICALS, INC. (US) | 2011-06-23 | — | — | US | disclosed |
| US-20100210665-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-08-19 | — | — | US | disclosed |
| US-20100210665-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-08-19 | — | — | US | disclosed |
| US-20100172975-A1 | TREATMENT OF HYPERPROLIFERATIVE DISORDERS WITH DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-07-08 | — | — | US | disclosed |
| US-20100172975-A1 | TREATMENT OF HYPERPROLIFERATIVE DISORDERS WITH DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-07-08 | — | — | US | disclosed |
| US-7709517-B2 | N-methyl-4-{4-[7-(4-cyano-3 -trifluoromethylphenyl)-6,8-dioxo-5,7-diazaspiro[3.4]oct-5-yl]-phenyl}butyramide; for treatment of hormone refractory prostate cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-05-04 | — | — | US | disclosed |
| US-7709517-B2 | N-methyl-4-{4-[7-(4-cyano-3 -trifluoromethylphenyl)-6,8-dioxo-5,7-diazaspiro[3.4]oct-5-yl]-phenyl}butyramide; for treatment of hormone refractory prostate cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-05-04 | — | — | US | disclosed |
| EP-1893196-A4 | DIARYLHYDANTOIN COMPOUNDS | UNIV CALIFORNIA (US) | 2009-03-18 | — | — | EP | disclosed |
| EP-2013187-A2 | DIARYLTHIOHYDANTOIN COMPOUNDS | The Regents of the University of California (US) | 2009-01-14 | — | — | EP | disclosed |
| US-20080139634-A2 | Use against hormone refractory prostate cancer; 1-(3-trifluoromethyl-4-cyanophenyl)-2-thioxo-3-(substituted phenyl)-imidazolidin-5-one and spiro ring derivatives thereof; androgen receptor antagonists with minimal agonist activity | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-06-12 | — | — | US | disclosed |
| US-20080139634-A2 | Use against hormone refractory prostate cancer; 1-(3-trifluoromethyl-4-cyanophenyl)-2-thioxo-3-(substituted phenyl)-imidazolidin-5-one and spiro ring derivatives thereof; androgen receptor antagonists with minimal agonist activity | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-06-12 | — | — | US | disclosed |
| WO-2007127010-A9 | DIARYLTHIOHYDANTOIN COMPOUNDS | UNIV CALIFORNIA (US) | 2008-05-22 | — | — | WO | disclosed |
| WO-2007127010-A9 | DIARYLTHIOHYDANTOIN COMPOUNDS | UNIV CALIFORNIA (US) | 2008-05-22 | — | — | WO | disclosed |
| EP-1893196-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-03-05 | — | — | EP | disclosed |
| WO-2007127010-A2 | DIARYLTHIOHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007127010-A2 | DIARYLTHIOHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-11-08 | — | — | WO | disclosed |
| US-20070254933-A1 | Use against hormone refractory prostate cancer; 1-(3-trifluoromethyl-4-cyanophenyl)-2-thioxo-3-(substituted phenyl)-imidazolidin-5-one and spiro ring derivatives thereof; selective androgen receptor modulators; non-steroidal, non-toxic, and tissue selective | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070254933-A1 | Use against hormone refractory prostate cancer; 1-(3-trifluoromethyl-4-cyanophenyl)-2-thioxo-3-(substituted phenyl)-imidazolidin-5-one and spiro ring derivatives thereof; selective androgen receptor modulators; non-steroidal, non-toxic, and tissue selective | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070004753-A1 | N-methyl-4-{4-[7-(4-cyano-3 -trifluoromethylphenyl)-6,8-dioxo-5,7-diazaspiro[3.4]oct-5-yl]-phenyl}butyramide; for treatment of hormone refractory prostate cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-01-04 | — | — | US | disclosed |
| US-20070004753-A1 | N-methyl-4-{4-[7-(4-cyano-3 -trifluoromethylphenyl)-6,8-dioxo-5,7-diazaspiro[3.4]oct-5-yl]-phenyl}butyramide; for treatment of hormone refractory prostate cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-01-04 | — | — | US | disclosed |
| WO-2006124118-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-11-23 | — | — | WO | disclosed |
| WO-2006124118-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10799489-B2 | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer | AR, SHBG, KLK3 | AR 1/4885GABRP 2633/4885GABRD 2171/4885 |
| US-20190328722-A1 | COMBINATION, APPLICATION THEREOF AND TREATMENT METHOD | CYP21A2, CYP17A1, NR5A1 | AR 5/4885GABRP 840/4885GABRD 639/4885 |
| US-20110152348-A1 | METHODS FOR TREATING ANDROGEN RECEPTOR DEPENDENT DISORDERS INCLUDING CANCERS | AR, ESRRB, ESRRA | AR 1/4885GABRP 820/4885GABRD 277/4885 |
| US-20180110764-A1 | Anti-Androgens For The Treatment Of Non-Metastatic Castrate-Resistant Prostate Cancer | AR, SHBG, KLK3 | AR 1/4885GABRP 2633/4885GABRD 2171/4885 |
| US-20240132452-A1 | DIARYLHYDANTOIN COMPOUNDS | BPHL, AR, SHBG | AR 2/4885GABRP 4199/4885GABRD 3464/4885 |
| US-20210113545-A1 | Pharmaceutical Composition Comprising a Benzoheterocyclic Compound and Androgen Receptor Pathway Modulator and Application Thereof | AR, NR5A1, CYP17A1 | AR 1/4885GABRP 496/4885GABRD 481/4885 |
| US-20140088129-A1 | ANTI-ANDROGENS FOR THE TREATMENT OF NON-METASTATIC CASTRATE-RESISTANT PROSTATE CANCER | AR, SHBG, KLK3 | AR 1/4885GABRP 2633/4885GABRD 2171/4885 |
| US-20120295944-A1 | TREATMENT OF HYPERPROLIFERATIVE DISORDERS WITH DIARYLHYDANTOIN COMPOUNDS | CDK4, CCNH, VHL | AR 113/4885GABRP 4700/4885GABRD 3973/4885 |
| US-20080139634-A2 | Use against hormone refractory prostate cancer; 1-(3-trifluoromethyl-4-cyanophenyl)-2-thioxo-3-(substituted phenyl)-imidazolidin-5-one and spiro ring derivatives thereof; androgen receptor antagonists with minimal agonist activity | AR, LHCGR, KLK3 | AR 1/4885GABRP 1272/4885GABRD 1538/4885 |
| US-20070254933-A1 | Use against hormone refractory prostate cancer; 1-(3-trifluoromethyl-4-cyanophenyl)-2-thioxo-3-(substituted phenyl)-imidazolidin-5-one and spiro ring derivatives thereof; selective androgen receptor modulators; non-steroidal, non-toxic, and tissue selective | AR, NR5A1, SHBG | AR 1/4885GABRP 1935/4885GABRD 2045/4885 |
| US-20230014124-A1 | HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | CRBN, MDM2, STUB1 | AR 799/4885GABRP 2391/4885GABRD 496/4885 |
| US-20220160695-A1 | ANTI-ANDROGENS FOR THE TREATMENT OF METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER | AR, KLK3, SHBG | AR 1/4885GABRP 2533/4885GABRD 2822/4885 |
| US-20180086718-A1 | Diarylhydantoin Compounds | BPHL, AR, SHBG | AR 2/4885GABRP 4199/4885GABRD 3464/4885 |
| US-20210000812-A1 | Anti-Androgens For The Treatment Of Non-Metastatic Castrate-Resistant Prostate Cancer | AR, SHBG, KLK3 | AR 1/4885GABRP 2633/4885GABRD 2171/4885 |
| US-10933059-B2 | Combination, application thereof and treatment method | CYP21A2, CYP17A1, NR5A1 | AR 5/4885GABRP 840/4885GABRD 639/4885 |
| US-11185592-B2 | Spirocyclic degronimers for target protein degradation | STUB1, UBE3C, UBE3A | AR 187/4885GABRP 4033/4885GABRD 1322/4885 |
| US-20230338351-A1 | Androgen Receptor Inhibitors For The Treatment Of Non-Metastatic Castration-Resistant Prostate Cancer In Subjects With Severe Hepatic Impairment | AR, KLK3, SHBG | AR 1/4885GABRP 1173/4885GABRD 1625/4885 |
| US-20070004753-A1 | N-methyl-4-{4-[7-(4-cyano-3 -trifluoromethylphenyl)-6,8-dioxo-5,7-diazaspiro[3.4]oct-5-yl]-phenyl}butyramide; for treatment of hormone refractory prostate cancer | AR, BRDT, GNRHR | AR 1/4885GABRP 480/4885GABRD 448/4885 |
| US-20210106688-A1 | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | STUB1, UBE3C, UBE3A | AR 187/4885GABRP 4033/4885GABRD 1322/4885 |
| US-20140031409-A1 | METHODS FOR TREATING ANDROGEN RECEPTOR DEPENDENT DISORDERS INCLUDING CANCERS | AR, ESRRB, ESRRA | AR 1/4885GABRP 820/4885GABRD 277/4885 |
| US-20180318277-A1 | Anti-Androgens For The Treatment Of Non-Metastatic Castrate-Resistant Prostate Cancer | AR, SHBG, KLK3 | AR 1/4885GABRP 2633/4885GABRD 2171/4885 |
| US-20100172975-A1 | TREATMENT OF HYPERPROLIFERATIVE DISORDERS WITH DIARYLHYDANTOIN COMPOUNDS | CDK4, CCNH, VHL | AR 113/4885GABRP 4700/4885GABRD 3973/4885 |
| US-20150157656-A1 | Method for Treatment of Castration-Resistant Prostate Cancer | IGFBP5, IGFBP2, IGFBP1 | AR 7/4885GABRP 1377/4885GABRD 1516/4885 |
| US-20210128541-A1 | ANDROGEN RECEPTOR INHIBITORS FOR THE TREATMENT OF NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER IN SUBJECTS WITH SEVERE HEPATIC IMPAIRMENT | AR, KLK3, SHBG | AR 1/4885GABRP 1173/4885GABRD 1625/4885 |
| US-20250333385-A1 | DIARYLHYDANTOIN COMPOUNDS | BPHL, AR, SHBG | AR 2/4885GABRP 4199/4885GABRD 3464/4885 |
| US-20190210974-A1 | DIARYLHYDANTOIN COMPOUNDS | BPHL, AR, SHBG | AR 2/4885GABRP 4199/4885GABRD 3464/4885 |
| US-10799488-B2 | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer | AR, SHBG, KLK3 | AR 1/4885GABRP 2633/4885GABRD 2171/4885 |
| US-20190262315-A1 | Treatment of Breast Cancer | BRCA1, TP53, TUBB6 | AR 2403/4885GABRP 3568/4885GABRD 3622/4885 |
| US-12303497-B2 | Anti-androgens for the treatment of metastatic castration-sensitive prostate cancer | AR, KLK3, SHBG | AR 1/4885GABRP 2533/4885GABRD 2822/4885 |
| US-10905768-B1 | Heterocyclic degronimers for target protein degradation | CRBN, MDM2, STUB1 | AR 799/4885GABRP 2391/4885GABRD 496/4885 |
| US-20170087132-A1 | Treatment of Breast Cancer | BRCA1, MKI67, BAX | AR 2292/4885GABRP 2593/4885GABRD 3792/4885 |
| US-20200079741-A1 | DIARYLHYDANTOIN COMPOUNDS | BPHL, AR, SHBG | AR 2/4885GABRP 4199/4885GABRD 3464/4885 |
| US-20170101384-A1 | ANDROGEN RECEPTOR ANTAGONISTS | AR, LHCGR, FSHR | AR 1/4885GABRP 352/4885GABRD 182/4885 |
| US-20150112082-A1 | DIARYLHYDANTOIN COMPOUNDS | BPHL, AR, SHBG | AR 2/4885GABRP 4199/4885GABRD 3464/4885 |
| US-20140296312-A1 | TREATMENT OF BREAST CANCER | BRCA1, BAX, BAD | AR 2166/4885GABRP 2459/4885GABRD 3707/4885 |
| US-20230190722-A1 | ANTI-ANDROGENS FOR THE TREATMENT OF METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER | AR, KLK3, SHBG | AR 1/4885GABRP 2533/4885GABRD 2822/4885 |
| US-20120190718-A1 | DIARYLTHIOHYDANTOIN COMPOUNDS | AR, SHBG, PTMS | AR 1/4885GABRP 3664/4885GABRD 2624/4885 |
| US-20180055915-A1 | COMPOSITIONS AND METHODS FOR TREATING PROSTATE CANCER | KLK3, ACP3, AR | AR 3/4885GABRP 4697/4885GABRD 4654/4885 |
| US-11963952-B2 | Anti-androgens for the treatment of metastatic castration-sensitive prostate cancer | AR, KLK3, SHBG | AR 1/4885GABRP 2533/4885GABRD 2822/4885 |
| US-20240165091-A1 | ANTI-ANDROGENS FOR THE TREATMENT OF METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER | AR, KLK3, SHBG | AR 1/4885GABRP 2533/4885GABRD 2822/4885 |
| US-20130034501-A1 | DIARYLHYDANTOIN COMPOUNDS | FAP, LEF1, LPXN | AR 11/4885GABRP 4859/4885GABRD 4634/4885 |
| US-20200354334-A1 | Process For The Preparation Of A Diarylthiohydantoin Compound | BPHL, CYP4X1, KLK3 | AR 27/4885GABRP 3804/4885GABRD 2494/4885 |
| US-10052314-B2 | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer | AR, SHBG, KLK3 | AR 1/4885GABRP 2633/4885GABRD 2171/4885 |
| US-20210069154-A1 | Treatment of Breast Cancer | BRCA1, TP53, TUBB6 | AR 2403/4885GABRP 3568/4885GABRD 3622/4885 |
| US-20190269667-A1 | Anti-Androgens For The Treatment Of Non-Metastatic Castrate-Resistant Prostate Cancer | AR, SHBG, KLK3 | AR 1/4885GABRP 2633/4885GABRD 2171/4885 |
| US-20140371284-A1 | IMIDAZOLIDINEDIONE COMPOUNDS AND THEIR USES | AR, CYP19A1, CYP17A1 | AR 1/4885GABRP 1462/4885GABRD 1592/4885 |
| US-10849888-B2 | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer | AR, SHBG, KLK3 | AR 1/4885GABRP 2633/4885GABRD 2171/4885 |
| US-20230405094-A1 | TREATMENT OR PREVENTION OF A DISEASE OR DISORDER | ADAMTS5, HEXD, ADAMTS1 | AR 3685/4885GABRP 3325/4885GABRD 3341/4885 |
| US-11723898-B2 | Androgen receptor inhibitors for the treatment of non-metastatic castration-resistant prostate cancer in subjects with severe hepatic impairment | AR, KLK3, SHBG | AR 1/4885GABRP 1173/4885GABRD 1625/4885 |
| US-20140343111-A1 | DIARYLTHIOHYDANTOIN COMPOUNDS | AR, SHBG, PTMS | AR 1/4885GABRP 3664/4885GABRD 2624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.